These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 2273982)
41. Comparative in vitro antifungal activity of amphotericin B lipid complex, amphotericin B and fluconazole. Carrillo-Muñoz AJ; Quindós G; Tur C; Ruesga M; Alonso R; del Valle O; Rodriguez V; Arévalo MP; Salgado J; Martin-Mazuelos E; Bornay-Llinares FJ; del Palacio A; Cuétara M; Gasser I; Hernández-Molina JM; Pemán J Chemotherapy; 2000; 46(4):235-44. PubMed ID: 10859429 [TBL] [Abstract][Full Text] [Related]
42. [In vitro antifungal activity of itraconazole, a new triazole antifungal agent, against clinical isolates from patients with systemic mycoses]. Uchida K; Matsuzaka A; Aoki K; Yamaguchi H Jpn J Antibiot; 1991 May; 44(5):562-70. PubMed ID: 1652654 [TBL] [Abstract][Full Text] [Related]
43. In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole. Carrillo-Muñoz AJ; Quindós G; Tur C; Ruesga MT; Miranda Y; del Valle O; Cossum PA; Wallace TL J Antimicrob Chemother; 1999 Sep; 44(3):397-401. PubMed ID: 10511410 [TBL] [Abstract][Full Text] [Related]
44. Yeasts and fluconazole susceptibility in the Philippines. Bulmer GS; Marquez ML; Co-Barcelona L; Fromtling RA Mycopathologia; 1999; 146(3):117-20. PubMed ID: 10823182 [TBL] [Abstract][Full Text] [Related]
45. Isavuconazole MIC distribution of 29 yeast species responsible for invasive infections (2015-2017). Desnos-Ollivier M; Bretagne S; Boullié A; Gautier C; Dromer F; Lortholary O; Clin Microbiol Infect; 2019 May; 25(5):634.e1-634.e4. PubMed ID: 30771532 [TBL] [Abstract][Full Text] [Related]
46. [The in vitro antifungal activities of fluconazole against pathogenic yeasts recently isolated from clinical specimens]. Yamaguchi H; Igari J; Kume H; Abe M; Oguri T; Kanno H; Kawakami S; Okuzumi K; Fukayama M; Ito A; Kawata K; Uchida K Jpn J Antibiot; 1997 Sep; 50(9):799-805. PubMed ID: 9394240 [TBL] [Abstract][Full Text] [Related]
47. Amphotericin B tolerance: a characteristic of Candida parapsilosis not shared by other Candida species. Seidenfeld SM; Cooper BH; Smith JW; Luby JP; Mackowiak PA J Infect Dis; 1983 Jan; 147(1):116-9. PubMed ID: 6822746 [TBL] [Abstract][Full Text] [Related]
48. Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine. Pfaller MA; Bale M; Buschelman B; Lancaster M; Espinel-Ingroff A; Rex JH; Rinaldi MG; Cooper CR; McGinnis MR J Clin Microbiol; 1995 May; 33(5):1104-7. PubMed ID: 7615713 [TBL] [Abstract][Full Text] [Related]
49. In vitro susceptibility of yeast isolates from the blood to fluconazole and amphotericin B. Dermoumi H Chemotherapy; 1992; 38(2):112-7. PubMed ID: 1591946 [TBL] [Abstract][Full Text] [Related]
50. [In vitro susceptibility to fluconazole of fungal strains freshly isolated from child patients with deep-seated mycoses]. Yamaguchi H; Uchida K Jpn J Antibiot; 1993 Aug; 46(8):647-53. PubMed ID: 8230734 [TBL] [Abstract][Full Text] [Related]
51. [In vitro sensitivity to 5-fluorocytosine and amphotericin B of yeasts of the Candida genus isolated in Barcelona]. Torres-Rodríguez JM; Sabaté M; Gallach C; Carrillo A; Madrenys N Enferm Infecc Microbiol Clin; 1990 Feb; 8(2):91-3. PubMed ID: 2098147 [TBL] [Abstract][Full Text] [Related]
52. Application of chip-based flow cytometry for amphotericin B and fluconazole susceptibility testing on Candida strains. Bouquet O; Kocsis B; Kilár F; Kustos I Methods Mol Biol; 2013; 968():149-54. PubMed ID: 23296892 [TBL] [Abstract][Full Text] [Related]
53. Interlaboratory evaluation of VITEK2 system and Sensititre YeastOne® for antifungal susceptibility testing of yeasts isolated from blood cultures against four antifungal agents. Farina C; Manso E; Andreoni S; Conte M; Fazii P; Lombardi G; Sanna S; Russello G New Microbiol; 2011 Apr; 34(2):195-201. PubMed ID: 21617832 [TBL] [Abstract][Full Text] [Related]
54. Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies. Nooney L; Matthews RC; Burnie JP Diagn Microbiol Infect Dis; 2005 Jan; 51(1):19-29. PubMed ID: 15629225 [TBL] [Abstract][Full Text] [Related]
55. Enhanced diallyl trisulfide has in vitro synergy with amphotericin B against Cryptococcus neoformans. Shen J; Davis LE; Wallace JM; Cai Y; Lawson LD Planta Med; 1996 Oct; 62(5):415-8. PubMed ID: 8923805 [TBL] [Abstract][Full Text] [Related]
56. Effect of culture media on in vitro susceptibility testing of fluconazole against some yeasts. Sekhon AS; Garg AK; Hamir Z Mycoses; 1991; 34(7-8):319-22. PubMed ID: 1803235 [TBL] [Abstract][Full Text] [Related]
57. Timed-kill curves for Cryptococcus neoformans isolated from patients with AIDS. Rodero L; Córdoba S; Cahn P; Soria M; Lucarini M; Davel G; Kaufman S; Canteros C; Guelfand L Med Mycol; 2000 Jun; 38(3):201-7. PubMed ID: 10892987 [TBL] [Abstract][Full Text] [Related]
58. Spectrum of in vitro antifungal activity of ditiocarb sodium. Allerberger F; Roberts G; Reisinger E; Dierich MP Arzneimittelforschung; 1991 Apr; 41(4):443-8. PubMed ID: 1650228 [TBL] [Abstract][Full Text] [Related]
59. Evaluation of 80% inhibition standards for the determination of fluconazole minimum inhibitory concentrations in three laboratories. Espinel-Ingroff A; Steele-Moore L; Galgiani JN Diagn Microbiol Infect Dis; 1994 Oct; 20(2):81-6. PubMed ID: 7867309 [TBL] [Abstract][Full Text] [Related]
60. Evaluation of Etest for determining in vitro susceptibility of yeast isolates to amphotericin B. Pfaller MA; Messer SA; Bolmström A Diagn Microbiol Infect Dis; 1998 Nov; 32(3):223-7. PubMed ID: 9884840 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]